Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Shares Shorted: Short Interest Up 264.3% in September

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 93,732 shares, a growth of 264.3% from the September 15th total of 25,732 shares. Based on an average trading volume of 1,091 shares, the days-to-cover ratio is presently 85.9 days.

Hansa Biopharma AB (publ) Price Performance

Hansa Biopharma AB (publ) stock remained flat at $3.29 during mid-day trading on Friday. The business has a fifty day moving average of $3.63 and a two-hundred day moving average of $3.17. Hansa Biopharma AB has a twelve month low of $2.90 and a twelve month high of $3.70.

Analysts Set New Price Targets

Separately, Danske initiated coverage on Hansa Biopharma AB (publ) in a research report on Tuesday, June 16th. They set a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Hansa Biopharma AB (publ) presently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system.